Description
GHK-Cu 50mg is the Core Research catalogue item for 50mg nominal of the copper complex of the tripeptide glycyl-histidyl-lysine, also written GHK-Cu. It is supplied as one lyophilised vial for in-vitro laboratory research only; not for human or veterinary use. The material and model-level science below must be distinguished from product-specific analytical results and finished-format performance.
What you receive and what needs verifying
| Field | What this product listing establishes |
|---|---|
| Exact catalogue item | GHK-Cu 50mg |
| Labelled amount | 50mg nominal; not an independently measured quantitative assay |
| Presentation | one lyophilised vial |
| Research identity | the copper complex of the tripeptide glycyl-histidyl-lysine, also written GHK-Cu |
| Supply boundary | In-vitro laboratory research only; no personal or veterinary use |
| Current price and stock | Shown by the live WooCommerce purchase panel; not fixed in this description |
The vial is the catalogue item: no cartridge, dispensing pen, buffer or administration accessory is stated as part of this purchase. The labelled milligram value is an amount per vial, not a prepared-solution concentration.
Before ordering, check the material identity, the form on the actual label and any information your assay needs from the applicable certificate. An unrelated paper, a general PubChem record or another catalogue format cannot establish a batch value for this particular item.
Which compound or format is the right laboratory item?
Different amount or format. GHK-Cu 50mg and 100mg are different labelled quantities. A vial and refill are different physical products. Neither item establishes the other’s supplied chemical form, measured copper content or lot test results.
Related formats and research alternatives
| Format or material | Catalogue listing | Evidence boundary |
|---|---|---|
| 50mg vial | GHK-Cu 50mg | This item |
| 50mg refill | GHK-Cu 50mg Refill | Separate catalogue record; verify its amount, components and lot evidence |
| 100mg vial | ghk-cu-100mg | Separate catalogue record; verify its amount, components and lot evidence |
| 100mg refill | ghk-cu-100mg-refill | Separate catalogue record; verify its amount, components and lot evidence |
| 100mg pen | ghk-cu-100mg-pen | Separate catalogue record; verify its amount, components and lot evidence |
Scientific research: mechanisms, measured results and limits
The following is a selected, model-specific evidence summary, not a systematic review, treatment recommendation or release test of this product. Read the study species, methods and measured endpoints beside each finding before transferring an interpretation to a different assay.
Copper coordination changes what must be specified
GHK is the tripeptide glycine–histidine–lysine, while GHK-Cu names a copper-associated complex. The underlying peptide sequence is useful reference information but does not, on its own, define copper stoichiometry, counter-ion composition, oxidation state, residual water or the mass basis used on a vial label. An analytical result for the free peptide should not be treated as automatically equivalent to a copper-complex assay. This distinction matters especially when comparing a 50mg vial, 50mg refill, and 100mg formats.
Epithelial-barrier and SIRT1–STAT3 experiments
In a 2025 investigation of a dextran-sulfate-sodium mouse colitis model and mouse epithelial/macrophage co-cultures, GHK-Cu was associated with changes in epithelial tight-junction proteins ZO-1 and occludin, inflammatory markers and SIRT1/p-STAT3 pathway measurements. A STAT3-silencing experiment removed the observed scratch-assay and junction-protein responses in that cell model. The authors also used molecular docking to nominate possible targets; docking is a hypothesis-generating technique, not confirmation that GHK-Cu directly binds SIRT1. These were non-human experimental systems. 1
Inflammatory pathways and the model-specific response
Park and colleagues investigated GHK-Cu in a lipopolysaccharide-induced acute lung-injury mouse model and reported changes in inflammatory readouts, including NF-κB and MAPK-associated signalling. A lung-injury model measures a particular inflammatory challenge; the presence of anti-inflammatory signals there does not establish the response of human skin, intestinal tissue, or any supplied laboratory batch. Results should be discussed as a pathway under investigation, not as a product-level health claim. 2
Matrix accumulation, fibrosis and oxidative stress
In bleomycin-related pulmonary-fibrosis research, Ma and colleagues examined oxidative-stress and inflammatory changes associated with GHK-Cu in a lung-injury model. Fibrotic tissue accumulation, collagen-related processes and tissue inflammation interact, but a measured reduction in fibrotic signals is not identical to clinically validated tissue rejuvenation. Experimental species, injury and dose context matter, and findings for a prepared test reagent do not assay the composition of this specific 50mg product. 3
Topical-formulation evidence is a separate evidence layer
Copper-tripeptide complexes have also been investigated in cosmetic and post-procedure topical formulations, including a study after CO2 laser resurfacing. The experimental vehicle, concentration and endpoint are integral to interpreting such studies. Results for a topical formulation cannot establish efficacy, safety or route suitability for a lyophilised research vial or cartridge; they also cannot verify the supplier’s copper content or batch purity. The value for researchers is the contrast between a compound-level mechanism and a formulated-product outcome. 4
How to interpret the evidence for this product
| Research context | Reported or relevant endpoint | Interpretation limit |
|---|---|---|
| Mouse colon and epithelial co-culture | ZO-1, occludin, p-STAT3 and scratch response | Not human mucosal healing evidence |
| LPS mouse lung-injury model | Inflammatory NF-κB/MAPK pathway markers | Distinct injury model and tissue |
| Bleomycin-related lung fibrosis model | Fibrotic and oxidative-stress markers | Does not imply clinical cosmetic restoration |
| Topical clinical formulation research | Formulation-specific appearance/recovery outcomes | Not a test of dry vial or refill |
Batch documentation before purchase
Core Research allows a pre-purchase batch-documentation enquiry. Use Batch Documentation or email info@core-research.net with the exact product name and presentation. An order or container lot number is not needed to ask the question before purchase; to match a supplied item after delivery, retain its lot identifier and order reference. The published delivery policy says a certificate is issued with a consignment where one exists for the supplied lot; that is not a promise of a current certificate for every item.
Ask whether documentation applies to the lot proposed for supply and identifies the tested chemical form, sample description, method, result, reporting basis, testing issuer and relevant dates. The difference between chromatographic peak-area purity, identity/mass and quantitative vial content matters.
For interpretation, use guide to reading a CoA, HPLC testing guide and mass-spectrometry guide. A theoretical molecular formula is not a batch-assay result, and a product label does not certify sterility.
For GHK-Cu 50mg, the material specification should distinguish copper-complex identity, copper and peptide mass bases, stoichiometry and counter-ion where relevant. A peptide HPLC purity percentage does not independently quantify total copper-complex content or the separate finished-cartridge performance.
Storage, receiving and laboratory quality control
A lyophilised vial is different from a liquid solution. Check the lot-specific storage document rather than importing a generic reconstitution or stability period.
Follow the supplied label and product-specific documentation for storage conditions, temperature excursions and expiry. The time limits for dry peptide, a mixed solution, or a liquid-filled cartridge can differ. No generic fixed storage term, purity threshold or cold-chain guarantee is inserted here without applicable evidence. See peptide storage guidance and research-product receiving checklist for general laboratory-record practices.
At receipt, compare the product name, labelled amount and presentation with your order. Inspect the vial closure or cartridge/packaging, record the lot identifier and retain the accompanying paperwork. If damaged, delayed or different from the order, record photographs and contact Core Research before using the material. This records receipt conditions; it does not substitute for an identity assay.
Ordering questions
Does the labelled milligram amount state purity or a prepared concentration?
No. 50mg is the catalogue-labelled quantity for this item. It does not by itself establish analytical content, purity, final liquid concentration, sample mass basis or number of experiments. The applicable material documentation and your laboratory’s own method establish those details.
Where is the product dispatched from and what is the delivery policy?
Core Research states that it dispatches from Birmingham, United Kingdom, using plain external packaging. Delivery service, charge and arrival estimates depend on the destination and order; see Shipping & Delivery. Tracking is provided in dispatch communications where available. There is no universal next-day delivery or free-shipping promise on this page.
Can I obtain an applicable certificate before ordering?
You can request information before ordering through Batch Documentation. Specify GHK-Cu 50mg, the vial presentation and any required test/method. Whether a particular current lot has a document, and what it actually reports, must be checked rather than assumed.
Can an institution request a quotation?
Yes. Institutional Procurement describes the written quotation and purchase-order-reference enquiry route. Include the institution, delivery details, exact product and quantity, and any lot or technical requirements. An enquiry does not itself reserve stock or guarantee credit terms.
Is this product suitable for human or veterinary use?
No. This listing is for in-vitro laboratory research only. Neither a positive model result nor a named medicinal compound establishes human-use suitability, and this page gives no preparation, dosing or administration instructions. See Research Use Only policy.
Order or enquire about GHK-Cu 50mg
Use the native product purchase panel to select the listed quantity and the checkout options available for your order. For identity, format, lot-documentation or delivery questions, contact Core Research before purchase. Current price and stock remain controlled by WooCommerce, not hard-coded in this description.
Selected research references
[1] Mao S et al. (2025). Exploring GHK-Cu in a DSS-induced colitis mouse model and mouse-cell co-cultures. Frontiers in Pharmacology. PMID 40672369. DOI 10.3389/fphar.2025.1551843. Primary research record.
[2] Park J et al. (2016). GHK-Cu and LPS-induced acute lung injury in mice. Oncotarget. DOI 10.18632/oncotarget.11168. Primary research record.
[3] Ma et al. (2020). Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis. Life Sciences. DOI 10.1016/j.lfs.2019.117139. Primary research record.
[4] Miller et al. (2006). Topical copper tripeptide complex after CO2 laser resurfacing: clinical cosmetic formulation context. Archives of Facial Plastic Surgery. DOI 10.1001/archfaci.8.4.252. Primary research record.


